SuperworthCastle Biosciences EV/EBIT CSTL
Enterprise value divided by operating profit over the last twelve months, one-off items taken out, since 2020.
- Today, Oct 23, 2026
- n/m
- an operating loss
- Last meaningful
- 31.0×
- May 2025
- 6-year median
- 68.6×
- 6-year range
- 28.4× to 124×
- Peer median
- 38.8×
Castle Biosciences has no meaningful EV/EBIT today: it made an operating loss of $32.1M over the last twelve months.
It was last meaningful in May 2025, at 31.0×.
On the days it had one over the last 6 years, its median was 68.6×, from 28.4× in Apr 2025 to 124× in Oct 2020.
EV/EBIT over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2025 | 31.0× | 28.4× | 38.6× |
| 2024 | n/m a value too high to mean anything | ||
| 2023 | n/m a value too high to mean anything | ||
| 2022 | n/m a value too high to mean anything | ||
| 2021 | n/m a value too high to mean anything | ||
| 2020 | 116× | 61.1× | 124× |
Against its peers
Companies in Medical - Diagnostics & Research nearest Castle Biosciences' size, closest first, today.
| Company | EV/EBIT |
|---|---|
| CSTLCastle Biosciences | n/m |
| NRCNRC Health | 38.8× |
| CDNACareDx | 29.3× |
| VCYTVeracyte | 27.2× |
| BLLNBillionToOne | 107× |
| LNTHLantheus | 20.6× |
| CAICaris Life Sciences | 56.4× |
| BIOBio-Rad Laboratories | 40.2× |
| Peer median | 38.8× |
What the EV/EBIT tells you
What the whole business costs against its operating profit. Enterprise value is the market value plus borrowings and minority interests, less cash. EBIT is operating profit before interest and tax, with one-offs taken out. Unlike PE it is not moved by how a company is financed.
Leases are left out of debt for every company. Banks earn on their balance sheet, so EV/EBIT does not describe them.
More on Castle Biosciences
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.